The global Botulinum toxin market accounted for $5814.9 million in 2021, and is expected to reach $13132.72 million by 2031, registering a CAGR of 8.6% from 2022 to 2031.
Botulinum toxin, one of the most poisonous biological substances known, and is a neurotoxin produced by the bacterium Clostridium botulinum. C. Botulinum elaborates eight antigenically distinguishable exotoxins (A, B, C1, C2, D, E, F and G). All serotypes interfere with neural transmission by blocking the release of acetylcholine, the principal neurotransmitter at the neuromuscular junction, causing muscle paralysis. The weakness induced by injection with botulinum toxin A usually lasts about three months.
Botulinum toxins now play a significant role in the management of a wide variety of medical conditions, especially strabismus and focal dystonia and some chronic conditions that respond only partially to medical treatment. The list of possible new indications is rapidly expanding. The aesthetic applications include correction of lines, creases and wrinkling all over the face, chin, neck, and chest to dermatological applications such as hyperhidrosis. Injections with botulinum toxin are generally well tolerated and side effects are few. A precise knowledge and understanding of the functional anatomy of the mimetic muscles is necessary to correctly use botulinum toxins in clinical practice.
The botulinum toxin market is expected to experience significant growth during the forecast period owing to surge in demand for cosmetic non-invasive surgical procedures, new product launches, increase in affordability and amendments in reimbursement policies to cover botulinum injections. In addition, rise in number of botulinum toxin procedure further facilitates the growth of the market. However, side effects associated with Botox procedures and high cost of these procedures are expected to impede the market growth in emerging region. In contrast, rise in investment in R&D activities by major manufacturers to explore the therapeutic use of botulinum toxin are anticipated to provide significant growth opportunities for the botulinum toxin market.
The Botulinum toxin market is segmented on the basis of product, application, end user and region. On the basis of product, the market is classified into botulinum toxin type A and botulinum toxin type B. On the basis of application, the market is divided into aesthetic and therapeutic. On the basis of end user, the market is classified into hospitals, specialty & dermatology clinics and others.
Region wise, the market is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides a comprehensive analysis of the key players that operate in the global botulinum toxin market. The key companies profiled in the report include Merz Pharma GmbH And Co. Kgaa, Abbvie Inc (Allergan), Ipsen Group, Revance Therapeutics Inc, Medy-Tox, Inc., Hugel, Inc., Galderma, Us Worldmed, Llc, Evolus Inc., and Daewoong Pharmaceutical.
Botulinum toxin, one of the most poisonous biological substances known, and is a neurotoxin produced by the bacterium Clostridium botulinum. C. Botulinum elaborates eight antigenically distinguishable exotoxins (A, B, C1, C2, D, E, F and G). All serotypes interfere with neural transmission by blocking the release of acetylcholine, the principal neurotransmitter at the neuromuscular junction, causing muscle paralysis. The weakness induced by injection with botulinum toxin A usually lasts about three months.
Botulinum toxins now play a significant role in the management of a wide variety of medical conditions, especially strabismus and focal dystonia and some chronic conditions that respond only partially to medical treatment. The list of possible new indications is rapidly expanding. The aesthetic applications include correction of lines, creases and wrinkling all over the face, chin, neck, and chest to dermatological applications such as hyperhidrosis. Injections with botulinum toxin are generally well tolerated and side effects are few. A precise knowledge and understanding of the functional anatomy of the mimetic muscles is necessary to correctly use botulinum toxins in clinical practice.
The botulinum toxin market is expected to experience significant growth during the forecast period owing to surge in demand for cosmetic non-invasive surgical procedures, new product launches, increase in affordability and amendments in reimbursement policies to cover botulinum injections. In addition, rise in number of botulinum toxin procedure further facilitates the growth of the market. However, side effects associated with Botox procedures and high cost of these procedures are expected to impede the market growth in emerging region. In contrast, rise in investment in R&D activities by major manufacturers to explore the therapeutic use of botulinum toxin are anticipated to provide significant growth opportunities for the botulinum toxin market.
The Botulinum toxin market is segmented on the basis of product, application, end user and region. On the basis of product, the market is classified into botulinum toxin type A and botulinum toxin type B. On the basis of application, the market is divided into aesthetic and therapeutic. On the basis of end user, the market is classified into hospitals, specialty & dermatology clinics and others.
Region wise, the market is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides a comprehensive analysis of the key players that operate in the global botulinum toxin market. The key companies profiled in the report include Merz Pharma GmbH And Co. Kgaa, Abbvie Inc (Allergan), Ipsen Group, Revance Therapeutics Inc, Medy-Tox, Inc., Hugel, Inc., Galderma, Us Worldmed, Llc, Evolus Inc., and Daewoong Pharmaceutical.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the botulinum toxin market analysis from 2021 to 2031 to identify the prevailing botulinum toxin market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the botulinum toxin market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global botulinum toxin market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Application
- Aesthetic
- Therapeutic
By Product
- Botulinum Toxin Type A
- Botulinum Toxin Type B
By End User
- Hospitals
- Specialty and Dermatology Clinics
- Others
By Region
- North America
- U. S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- REVANCE THERAPEUTICS INC
- Medy-Tox, Inc.
- GALDERMA
- US WORLDMED, LLC
- Abbvie Inc (Allergan)
- DAEWOONG PHARMACEUTICAL
- Ipsen Group
- MERZ PHARMA GMBH AND CO. KGAA
- HUGEL, INC.
- EVOLUS INC.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
CHAPTER 4: BOTULINUM TOXIN MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Botulinum Toxin Type A
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Botulinum Toxin Type B
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
CHAPTER 5: BOTULINUM TOXIN MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Aesthetic
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Therapeutic
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: BOTULINUM TOXIN MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospitals
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Specialty and Dermatology Clinics
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Others
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: BOTULINUM TOXIN MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Product
7.2.3 North America Market size and forecast, by Application
7.2.4 North America Market size and forecast, by End User
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Product
7.2.5.1.3 Market size and forecast, by Application
7.2.5.1.4 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Product
7.2.5.2.3 Market size and forecast, by Application
7.2.5.2.4 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Product
7.2.5.3.3 Market size and forecast, by Application
7.2.5.3.4 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Product
7.3.3 Europe Market size and forecast, by Application
7.3.4 Europe Market size and forecast, by End User
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Product
7.3.5.1.3 Market size and forecast, by Application
7.3.5.1.4 Market size and forecast, by End User
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Product
7.3.5.2.3 Market size and forecast, by Application
7.3.5.2.4 Market size and forecast, by End User
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Product
7.3.5.3.3 Market size and forecast, by Application
7.3.5.3.4 Market size and forecast, by End User
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Product
7.3.5.4.3 Market size and forecast, by Application
7.3.5.4.4 Market size and forecast, by End User
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Product
7.3.5.5.3 Market size and forecast, by Application
7.3.5.5.4 Market size and forecast, by End User
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Product
7.3.5.6.3 Market size and forecast, by Application
7.3.5.6.4 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Product
7.4.3 Asia-Pacific Market size and forecast, by Application
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Product
7.4.5.1.3 Market size and forecast, by Application
7.4.5.1.4 Market size and forecast, by End User
7.4.5.2 China
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Product
7.4.5.2.3 Market size and forecast, by Application
7.4.5.2.4 Market size and forecast, by End User
7.4.5.3 Australia
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Product
7.4.5.3.3 Market size and forecast, by Application
7.4.5.3.4 Market size and forecast, by End User
7.4.5.4 India
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Product
7.4.5.4.3 Market size and forecast, by Application
7.4.5.4.4 Market size and forecast, by End User
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Product
7.4.5.5.3 Market size and forecast, by Application
7.4.5.5.4 Market size and forecast, by End User
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Product
7.4.5.6.3 Market size and forecast, by Application
7.4.5.6.4 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Product
7.5.3 LAMEA Market size and forecast, by Application
7.5.4 LAMEA Market size and forecast, by End User
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Product
7.5.5.1.3 Market size and forecast, by Application
7.5.5.1.4 Market size and forecast, by End User
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Product
7.5.5.2.3 Market size and forecast, by Application
7.5.5.2.4 Market size and forecast, by End User
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Product
7.5.5.3.3 Market size and forecast, by Application
7.5.5.3.4 Market size and forecast, by End User
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Product
7.5.5.4.3 Market size and forecast, by Application
7.5.5.4.4 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Players
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 REVANCE THERAPEUTICS INC
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Medy-Tox, Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 galderma
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 US WORLDMED, LLC
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Abbvie Inc (Allergan)
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 DAEWOONG PHARMACEUTICAL
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Ipsen Group
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 MERZ PHARMA GMBH AND CO. KGAA
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 HUGEL, INC.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 EVOLUS INC.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
Executive Summary
According to this report, titled, 'Botulinum Toxin Market,' the botulinum toxin market size was valued at $5.8 billion in 2021, and is estimated to reach $13.1 billion by 2031, growing at a CAGR of 8.6% from 2022 to 2031.Botulinum toxin, also called as'miracle poison,' is one of the most poisonous biological substances. It is a neurotoxin produced by the bacterium Clostridium botulinum, an anaerobic, gram-positive, spore-forming rod commonly found on plants, in soil, water and the intestinal tracts of animals. Botulinum toxin induces weakness of striated muscles by inhibiting transmission of alpha motor neurons at the neuromuscular junction. This has led to its use in conditions with muscular overactivity, such as dystonia. Transmission is also inhibited at gamma neurons in muscle spindles, which may alter reflex overactivity. The toxin also inhibits release of acetylcholine in all parasympathetic and cholinergic postganglionic sympathetic neurons. This has generated interest in its use as a treatment for overactive smooth muscles (for example, in achalasia) or abnormal activity of glands (for example, hyperhidrosis).
The key factors that drive the growth of the botulinum toxin market size include increase in geriatric population, rise in number of licensed medical centers, and surge in self-awareness among population regarding the physical appearance. Moreover, the increase in usage of botulinum toxin injection in several aesthetic procedures including the treatment of glabellar lines, chemical browlift, and forehead lines are some of the major botulinum toxin market trends. However, side effects associated with botulinum toxin procedures and high cost of procedures are likely to hamper the growth of the market during the forecast period. Conversely, rise in investment in R&D activities by major manufacturers to explore the therapeutic use of botulinum toxin are expected to provide numerous opportunities for market growth during the forecast period.
By product, the botulinum toxin A segment dominated the botulinum toxin industry in 2021 and is expected to remain dominant during the forecast period, owing to rise in customer preference due to advantages including minimal pain, no blood loss, and lack of scarring during the procedure. In addition, Botulinum toxin type-A has been increasingly utilized to treat chronic migraine, tension-type headache, and other primary neurological disorders which further propel the market growth.
By application, the therapeutic segment dominated the market in 2021 and is expected to remain dominant during the forecast period, owing to heavy investment for extensive R&D of therapeutics products and its expanding applications in various disease categories such as chronic migraine, conditions such as hyperhidrosis, and over-reactive bladders.
By end user, the specialty and dermatology clinic segment dominated the botulinum toxin Industry in 2021 and is expected to remain dominant during the forecast period, owing to increase in number of dermatology and rise in expenditure by governments to improve the healthcare industry. Moreover, higher number of non-invasive cosmetic procedures performed in the specialty and dermatology clinics as compared to hospitals which further drives the segment growth.
Region wise, North America has the highest botulinum toxin market share and registered a significant CAGR during the forecast period. The dominance is due to higher number of botulinum toxin procedures, increase in number of approvals for aesthetic products, a strong presence of key players, and advancements in medical and aesthetic sector. Asia-Pacific is projected to register the highest CAGR during the botulinum toxin market forecast. Increase in geriatric population, rise in awareness among young population regarding aesthetics, growth in healthcare expenditures, and surge in adoption of Botox products are the key driving factors that boost the growth of the market in the region.
KEY FINDINGS OF STUDY
On the basis of botulinum toxin market analysis, the botulinum toxin type A segment dominated the market in 2021 and is expected to continue this trend during the forecast period.On the basis of application, the therapeutic segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
On the basis of end user, specialty and dermatology clinic segment is projected to grow at a higher CAGR during the forecast period.
On the basis of region, North America held the largest botulinum toxin market share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Revance Therapeutics Inc.
- Medy-Tox, Inc.
- Galderma
- US Worldmed, LLC
- Abbvie Inc (Allergan)
- Daewoong Pharmaceutical
- Ipsen Group
- Merz Pharma GmbH and Co. KGaA
- Hugel, Inc.
- Evolus Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 215 |
| Published | October 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 5814.9 million |
| Forecasted Market Value ( USD | $ 13132.72 million |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
